Aegis Equities Research has published a commissioned report for the Health & Life Science Review, June 2007 This report can be viewed at:
http://www.aer.com.au
on the Home page.

The June 2007 edition of the Health & Life Science Quarterly Blue Book profiles niche life sciences companies, with a focus on company strategies, key projects and significant milestones. Some financial data is also presented. In this feature article AER looks at the impact of product recalls in the healthcare device sector. The article contains recent examples, which serve to outline the potential damage to a company's reputation that can result from regular recalls while demonstrating the advantages competitors can gain over those unfortunate enough to be involved in a recall.

NB: This report has been commissioned and as such Aegis has received a fee for its publication. However, under no circumstances has Aegis been influenced, either directly or indirectly, in making statements and/or recommendations contained in this report.

About Aegis Equities Research

Aegis Equities Research is Australia's first truly independent equities research firm, established to provide incisive equities analysis to fund managers, stockbrokers, financial planners and retail investors.

 

Contact

Peter Leodaritsis
Managing Director
Aegis Equities Research



Related Companies

Aegis Equities Research


Related Industry Topics: